Prestige Consumer Healthcare Inc has a consensus price target of $83.6 based on the ratings of 5 analysts. The high is $104 issued by RBC Capital on March 17, 2023. The low is $70 issued by Jefferies on May 10, 2022. The 3 most-recent analyst ratings were released by DA Davidson, Canaccord Genuity, and DA Davidson on June 21, 2024, May 21, 2024, and May 16, 2024, respectively. With an average price target of $79.33 between DA Davidson, Canaccord Genuity, and DA Davidson, there's an implied 12.72% upside for Prestige Consumer Healthcare Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
06/21/2024 | Buy Now | 32.14% | DA Davidson | Linda Bolton Weiser | $65 → $93 | Upgrade | Neutral → Buy | Get Alert |
05/21/2024 | Buy Now | 13.67% | Canaccord Genuity | Susan Anderson | $80 → $80 | Maintains | Buy | Get Alert |
05/16/2024 | Buy Now | -7.64% | DA Davidson | Linda Bolton Weiser | $65 → $65 | Maintains | Neutral | Get Alert |
06/26/2023 | Buy Now | -14.75% | DA Davidson | Linda Bolton Weiser | → $60 | Reiterates | Neutral → Neutral | Get Alert |
05/08/2023 | Buy Now | -14.75% | DA Davidson | Linda Bolton Weiser | → $60 | Reiterates | → Neutral | Get Alert |
03/17/2023 | Buy Now | 47.77% | RBC Capital | Sabahat Khan | $107 → $104 | Maintains | Sector Perform | Get Alert |
02/17/2023 | Buy Now | 0.88% | Oppenheimer | Rupesh Parikh | $72 → $71 | Maintains | Outperform | Get Alert |
01/13/2023 | Buy Now | 2.3% | Oppenheimer | Rupesh Parikh | $63 → $72 | Maintains | Outperform | Get Alert |
11/17/2022 | Buy Now | 0.88% | Canaccord Genuity | Susan Anderson | → $71 | Initiates | → Buy | Get Alert |
05/10/2022 | Buy Now | -0.54% | Jefferies | Stephanie Wissink | $65 → $70 | Upgrade | Hold → Buy | Get Alert |
05/09/2022 | Buy Now | -10.49% | Oppenheimer | Rupesh Parikh | → $63 | Upgrade | Perform → Outperform | Get Alert |
05/09/2022 | Buy Now | -14.75% | DA Davidson | Linda Bolton Weiser | $63 → $60 | Maintains | Neutral | Get Alert |
11/15/2021 | Buy Now | -10.49% | DA Davidson | Linda Bolton Weiser | — | Maintains | Neutral | Get Alert |
08/06/2021 | Buy Now | -13.33% | DA Davidson | Linda Bolton Weiser | — | Maintains | Neutral | Get Alert |
The latest price target for Prestige Consumer (NYSE:PBH) was reported by DA Davidson on June 21, 2024. The analyst firm set a price target for $93.00 expecting PBH to rise to within 12 months (a possible 32.14% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Prestige Consumer (NYSE:PBH) was provided by DA Davidson, and Prestige Consumer upgraded their buy rating.
The last upgrade for Prestige Consumer Healthcare Inc happened on June 21, 2024 when DA Davidson raised their price target to $93. DA Davidson previously had a neutral for Prestige Consumer Healthcare Inc.
There is no last downgrade for Prestige Consumer.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prestige Consumer, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prestige Consumer was filed on June 21, 2024 so you should expect the next rating to be made available sometime around June 21, 2025.
While ratings are subjective and will change, the latest Prestige Consumer (PBH) rating was a upgraded with a price target of $65.00 to $93.00. The current price Prestige Consumer (PBH) is trading at is $70.38, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.